A PYMNTS Company

EU: Novartis Recommended For EU Approval

 |  March 11, 2015

Zykadia from Novartis was recommended for EU approval to address treatment for adult patients suffering from anapestic lymphoma kinase -positive advanced non-small cell lung cancer also known as ALK+NSCLC, which has been treated previously with crizotinib.

If approved, this would be the first treatment option for patients in Europe.


Full Content: Mondaq


Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.